Have a feature idea you'd love to see implemented?
Let us know!
ACRS Aclaris Therapeutics Inc
Price (delayed)
$1.29
Market cap
$92.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
$69.2M
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The
Highlights
ACRS's debt has plunged by 100% YoY
Aclaris Therapeutics's EPS has increased by 47% YoY and by 25% QoQ
ACRS's gross profit is down by 24% YoY but it is up by 4.4% from the previous quarter
Aclaris Therapeutics's gross margin has decreased by 26% YoY
ACRS's equity is down by 26% YoY and by 6% QoQ
Key stats
What are the main financial stats of ACRS
Market
Valuations
Earnings
Shares outstanding
71.34M
Market cap
$92.03M
Enterprise value
$69.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
2.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
Revenue
$32.02M
EBIT
-$59.05M
EBITDA
-$58.11M
Free cash flow
-$65.1M
Per share
Balance sheet
Liquidity
EPS
-$0.82
Free cash flow per share
-$0.91
Book value per share
$1.88
Revenue per share
$0.45
TBVPS
$2.26
Total assets
$161.07M
Total liabilities
$27.25M
Debt
$0
Equity
$133.82M
Working capital
$101.95M
Debt to equity
0
Current ratio
7.5
Quick ratio
7.1
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-181.5%
Gross margin
42.6%
Net margin
-183.3%
Operating margin
-278%
Return on assets
-31.3%
Return on equity
-39.8%
Return on invested capital
-46.1%
Return on capital employed
-40.6%
Return on sales
-184.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRS stock price
How has the Aclaris Therapeutics stock price performed over time
Intraday
2.38%
1 week
10.26%
1 month
11.21%
1 year
-74.04%
YTD
22.86%
QTD
12.17%
Financial performance
How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$32.02M
Gross profit
$13.65M
Operating income
-$89.01M
Net income
-$58.68M
Gross margin
42.6%
Net margin
-183.3%
ACRS's net margin is up by 46% YoY and by 26% from the previous quarter
The company's net income rose by 44% YoY and by 24% QoQ
Aclaris Therapeutics's gross margin has decreased by 26% YoY
ACRS's gross profit is down by 24% YoY but it is up by 4.4% from the previous quarter
Growth
What is Aclaris Therapeutics's growth rate over time
Valuation
What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
2.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
Aclaris Therapeutics's EPS has increased by 47% YoY and by 25% QoQ
ACRS's P/B is 81% below its 5-year quarterly average of 3.7 and 43% below its last 4 quarters average of 1.2
ACRS's equity is down by 26% YoY and by 6% QoQ
ACRS's P/S is 95% below its 5-year quarterly average of 62.0 and 62% below its last 4 quarters average of 7.6
The company's revenue rose by 2.9% QoQ and by 2.7% YoY
Efficiency
How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has increased by 45% YoY and by 26% QoQ
The ROA has increased by 27% YoY and by 16% from the previous quarter
The company's return on equity rose by 27% YoY and by 18% QoQ
Aclaris Therapeutics's return on invested capital has increased by 24% YoY and by 16% QoQ
Dividends
What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRS.
Financial health
How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total liabilities has plunged by 51% YoY and by 15% from the previous quarter
Aclaris Therapeutics's quick ratio has increased by 35% YoY and by 11% QoQ
ACRS's debt is 100% less than its equity
ACRS's debt has plunged by 100% YoY
ACRS's equity is down by 26% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.